Kannel William B, Giordano Michael
Framingham Heart Study, Framingham, Massachusetts 01702-5728, USA.
Am J Cardiol. 2004 Oct 1;94(7):901-6. doi: 10.1016/j.amjcard.2004.06.025.
This report reviews current data pertaining to the development of dyslipidemia during treatment with protease inhibitors and the associated risk for cardiovascular disease in patients who have the human immunodeficiency virus. Most protease inhibitors used to manage the human immunodeficiency virus and the acquired immunodeficiency syndrome are associated with prompt, marked, and sustained increases in serum lipid levels that are consistent with an increased 10-year risk for coronary heart disease as determined in the Framingham Heart Study. Management of lipid elevations in patients who use protease inhibitors is discussed. Novel protease inhibitors, which have minimal effects on lipid profiles, may have a role in the long-term management of the human immunodeficiency virus.
本报告回顾了与蛋白酶抑制剂治疗期间血脂异常的发生以及人类免疫缺陷病毒（HIV）感染者心血管疾病相关风险有关的现有数据。大多数用于治疗人类免疫缺陷病毒和获得性免疫缺陷综合征的蛋白酶抑制剂会导致血清脂质水平迅速、显著且持续升高，这与弗明汉姆心脏研究确定的冠心病10年风险增加相一致。文中讨论了使用蛋白酶抑制剂患者脂质升高的管理方法。对脂质谱影响极小的新型蛋白酶抑制剂可能在人类免疫缺陷病毒的长期管理中发挥作用。
